Compare Schlumberger NV (SLB) vs 10X Genomics Inc (TXG) Price & Performance

SLB trades at $57.10, down 0.71% on the day, but remains near recent highs with a bullish technical trend. The company reported three consecutive quarterly earnings beats, with Q3 2026 expected at $0.62 EPS. Recent news highlights the $3.4 billion acquisition of Kelvion, expanding SLB's data center cooling business. Revenue for 2025 was $35.71 billion with a net income margin of 8.53%, though margins have softened from prior years. Analyst consensus is strongly bullish with an average price target of $63.00.

The outlook for SLB is positive, driven by strategic diversification into data centers and solid operational cash flow near $6.5 billion annually. Key risks include exposure to oil price volatility and integration challenges from the Kelvion deal. With 85% of analysts rating it a buy, the stock offers upside potential but requires monitoring of execution on new growth initiatives.

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.